David Thomson, Ph.D.

Chief Development Officer

David guides preclinical strategy at Precision, helping the team identify gene therapies and cell therapies that will shine in the clinic and go on to become commercial products. He joined Precision from Shire Pharmaceuticals, a biotechnology company focused on rare disease treatments, where he served as Senior Vice President and Global Head of Research and Nonclinical Development. Prior to Shire David worked in a number of pharma and biotech companies, both large and small, including Amgen and Boehringer-Ingelheim. He received his Ph.D. in organic chemistry from the University of Toronto and completed post-doctoral work at Yale University. When not at Precision he can be found swinging a kettle bell and despite being a Scot, David does not golf but he does play the bagpipes, albeit poorly.